Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds
to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1
(PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety,
tolerability and efficacy of CK-301 when administered intravenously as a single agent to
subjects with selected recurrent or metastatic cancers.